Searched for
JANUVIA
Generics of MSD diabetes pill set to flood market as patent expiresAccording to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...- Merck & Co to expand in India, favourable IPR ruling encourages co to invest moreThe Delhi High Court decision on its anti-diabetes drug Januvia is among the factors encouraging Merck to invest in India, global CEO Kenne...
- Glenmark evaluating legal options over diabetes drugs setbackGlenmark said it is evaluating legal options after the Delhi HC restrained it from manufacturing & selling generic version of MSD's anti-di...
- Blow to Glenmark: Delhi High Court restrains it from making Zita & Zita-MetHC restrained Glenmark from making, selling, advertising, distributing or exporting its anti-diabetes drugs Zita and Zita-Met.
- Lifestyle and death: Yoga is just a small step in countering Big Food and Big PharmaIndeed, recent studies show that India is undergoing an ‘epidemiological transition’ consistent with lifestyle changes.
- Glenmark's anti-diabetes drugs shake up Indian anti-diabetes marketThe company has raked in Rs 16 crore in just 8 months since drug was launched.
- MSD-Glenmark drug patent row: Delhi High Court reserves verdictThe Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.
- Sun Pharma gets FDA nod for generic version of JanuviaThis comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the sa...
- Delhi High Court seeks Glenmark's response on US drug giant MSD's appealJustice S Ravindra Bhat and SK Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the sing...
- Drug patent row: Delhi High Court seeks Glenmark's response by May 22The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation o...
- No interim relief to Merck against Glenmark’s diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...
- Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugsA unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
- Best way to expand in India is via partnerships: Adam H Schechter, MerckA strong growth in the antidiabetic drugs market — 25% growth year-on year — has helped Merck boost sales of its blockbuster products.
- The best way to expand in India is through partnerships, says Merck’s SchechterAdam H Schechter, Merck’s executive vicepresident and president, says the global pharma major is committed to India despite the challenges.
- Merck arm to sell cheap diabetes drugThis is perhaps one of the few instances where a drug is cheaper in India, as against its price in other developed markets. (Januvia is pri...
- 'Antibiotic resistance is a challenge'Naveen Rao, MSD Pharmaceuticals India MD spoke to Nina Mehta about the company's plans for the future and what makes them stand out from th...
- Novartis ties up with USV to market Galvus in IndiaNovartis has tied up with leading healthcare company - USV - to market its anti-diabetic product Galvus.
- Merck secures 2 patents in India, to pursue moreUS-based Merck has received patent approval from the Indian Patent Office for two of its upcoming drugs for dyslipidemia and obesity.
- MSD Pharma launches JANUVIA for diabetic careDrug firm MSD Pharmaceuticals today launched its patent medicine under the brand name 'JANUVIA' in diabetic care segment and aims to tap fo...
Load More
